Corporate Connect analyst Marc Sinatra has raised his target price on Antisense Therapeutics (ASX: ANP) to $0.43 after a placebo-controlled phase II trial involving potential competitor Sarepta Therapeutics’ SRP-9001 gene therapy failed to demonstrate an improvement in clinical function in 41 patients.
“It is never nice to look at the bright side of a drug failure, but this has significant implications for the value of ANP,” says Sinatra.
For full details refer to the detailed report below or click here to download your copy.
